成纖維細(xì)胞生長(zhǎng)因子15(FGF15)活性蛋白
Active Fibroblast Growth Factor 15 (FGF15)
- 編號(hào)APL154Ra01
- 物種Rattus norvegicus (Rat,大鼠)相同的名稱,不同的物種。
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.)
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)6.6
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價(jià)格¥ 1858 ¥ 4644¥ 9288¥ 27864¥ 69660
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)

Fibroblast growth factor 15 is a protein in mouse encoded by the Fgf15 gene. It is a member of the fibroblast growth factor (FGF) family but, like FGF19, FGF21 and FGF23, has endocrine functions. FGF15 subsequently acts on a cell surface receptor complex in hepatocytes to repress bile acid synthesis and gluconeogenesis, and to stimulate glycogen and protein synthesis.Besides, Fibroblast Growth Factor Receptor 4 (FGFR4) has been identified as an interactor of FGF15, thus a binding ELISA assay was conducted to detect the interaction of recombinant rat FGF15 and recombinant rat FGFR4. Briefly, FGF15 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μl then transferred to FGFR4-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-FGF15 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μl stop solution to the wells and read at 450nm immediately. The binding activity of FGF15 and FGFR4 was shown in Figure 1, and this effect was in a dose dependent manner.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Endocrinology. | Naringenin Prevents Obesity, Hepatic Steatosis, and Glucose Intolerance in Male Mice Independent of Fibroblast Growth Factor 21[PubMed: 25774553] |
Inflammatory Bowel Diseases | Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation[pubmed:27580383] |
J Lipid Res. | Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis.[pubmed:28130274] |
BMC Endocrine Disorders | The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance[10.1186/s12902-017-0211-5] |
Journal?of?Physiology?and?Biochemistry | The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice[Pubmed:29468415] |
Developmental?Cell | FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis[Pubmed: 30745141] |
Endocrinology | Interactions between the gravitostat and the fibroblast growth factor system for the regulation of body weight[] |
Food & Function | Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis[Pubmed: 31626262] |
Journal of Translational Medicine | Gut microbiota from coronary artery disease patients contributes to vascular dysfunction in mice by regulating bile acid metabolism and immune activation[Pubmed: 33036625] |
Chin Med | Si-Wu-Tang ameliorates fibrotic liver injury via modulating intestinal microbiota and bile acid homeostasis[34736501] |
Int J Biol Sci | Dynamics of the gut-liver axis in rats with varying fibrosis severity[Pubmed:35637968] |